Archives: Communications

Laurent Pharmaceuticals announces positive outcomes of pre-planned interim DSMB safety review and futility analysis for phase 2 RESOLUTION study in hospitalized COVID-19 patients. Read more here

According to the new study by Unruly, more than two-thirds (67%) of UK advertising professionals think connected TV (CTV) is a more effective ad channel than linear TV. Read more here

Rellevate, Inc., a fintech company dedicated to empowering consumers through leading-edge financial and payment services, announced it has joined the UKG Technology Partner Network, a collaborative ecosystem of organizations creating solution extensions for UKG Dimensions and UKG Ready to amplify and elevate the employee experience. Read more here

Unruly Splats are programmable floor buttons that students code with an app on a tablet or computer to light up, make sounds, and collect points when stomped on (they also have a virtual version that kids can play in the app). Read more here

Pregnancy is a time of extraordinary change for the body. Among the many things to expect while expecting, there is a radical shift in nutritional needs for both the mother-to-be and her baby. Read more here

Kalion Inc. , along with 8 other companies, was selected by the U.S. Department of Energy to receive $5.7 million in funding with the Agile BioFoundry consortium (agilebiofoundry.org) to advance the fundamental understanding of industrial biotechnology. Read more here

Narragansett Beer CEO Mark Hellendrung has owned the iconic Rhode Island beer brand for fifteen years, and it will soon mark its 130th anniversary with the opening of the Providence brewery. Read more here

Premama Wellness, a Providence-based startup that sells supplements for maternity wellness, has attracted its first institutional investor since launching in 2011: District Ventures Capital, a Canadian venture capital fund hyper-focused on the food, beverage and health and wellness sectors. Read more here.

Laurent Pharmaceuticals Inc., a Montreal-based biopharmaceutical company, today announced that it has obtained the approval from Health Canada to initiate RESOLUTION, a Phase 2 randomized placebo-controlled trial testing once-a-day oral LAU-7b as a potential drug candidate to help combat the COVID-19 disease. The trial, which is planned to start imminently in multiple hospitals in Canada,…